81 related articles for article (PubMed ID: 8658708)
1. Pharmacokinetic characteristics of two types of liposomal FK 506.
Yagura K; Nakajima Y; Ko S; Kanehiro H; Nakano H
Transplant Proc; 1996 Jun; 28(3):1390-1. PubMed ID: 8658708
[No Abstract] [Full Text] [Related]
2. Liposomal tacrolimus and intestinal drug concentration.
Dutta S; Mezei M; Lee TD; McAlister VC
Transplant Proc; 1998 Sep; 30(6):2651-2. PubMed ID: 9745533
[No Abstract] [Full Text] [Related]
3. Interaction between FK 506 and diltiazem in an animal model.
Regazzi MB; Iacona I; Alessiani M; Spada M; Vaccarisi S; Villani P; Molinaro M
Transplant Proc; 1996 Apr; 28(2):1017-8. PubMed ID: 8623215
[No Abstract] [Full Text] [Related]
4. The pharmacokinetic benefits of newly developed liposome-incorporated FK506.
Ko S; Nakajima Y; Kanehiro H; Yoshimura A; Nakano H
Transplantation; 1994 Nov; 58(10):1142-4. PubMed ID: 7526494
[No Abstract] [Full Text] [Related]
5. Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate.
Yoshimura N; Yura H; Hamashima T; Oka T; Takakura Y; Hadhida M
Transplant Proc; 1998 Jun; 30(4):1029-30. PubMed ID: 9636415
[No Abstract] [Full Text] [Related]
6. [Tacrolimus hydrate (tacrolimus)].
Matsuda J
Nihon Rinsho; 2004 Dec; 62 Suppl 12():465-8. PubMed ID: 15658364
[No Abstract] [Full Text] [Related]
7. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity.
McAlister VC; Keshavamurthy M; Lee TD
Transplant Proc; 1999; 31(1-2):1110. PubMed ID: 10083495
[No Abstract] [Full Text] [Related]
8. No effect of water deprivation for 48 hours on the pharmacokiinetics of intravenous tacrolimus in rats.
Son IJ; Moon YJ; Lee MG; Sohn YT
Res Commun Mol Pathol Pharmacol; 2000; 107(3-4):279-89. PubMed ID: 11484882
[TBL] [Abstract][Full Text] [Related]
9. Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis.
Chuang YC; Tyagi P; Huang HY; Yoshimura N; Wu M; Kaufman J; Chancellor MB
Neurourol Urodyn; 2011 Mar; 30(3):421-7. PubMed ID: 20860016
[TBL] [Abstract][Full Text] [Related]
10. Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration.
Zhu Q; Guo T; Xia D; Li X; Zhu C; Li H; Ouyang D; Zhang J; Gan Y
J Pharm Pharmacol; 2013 Aug; 65(8):1107-17. PubMed ID: 23837579
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients.
Lumlertgul D; Noppakun K; Rojanasthien N; Kanchanarattanakorn K; Jittikanont S; Manoyot A; Bunnachak D; Ophascharoensuk V
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S73-8. PubMed ID: 17044457
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus.
Alessiani M; Regazzi M; Abbiati F; Ferrari P; Molinaro M; Iacona I; Klersy C; Viezzoli A; Fayer F; Pileggi A; Zitelli E; Burroni B; Scandone M; Dionigi P; Zonta A
Transplant Proc; 2000 Sep; 32(6):1214-5. PubMed ID: 10995915
[No Abstract] [Full Text] [Related]
13. Tacrolimus disposition in the ascitic fluid of a bone marrow transplant patient.
Ibrahim RB; Abidi MH; Al-Kadhimi Z; Uberti JP; Edwards DJ
Ann Pharmacother; 2010 May; 44(5):939-40. PubMed ID: 20371750
[No Abstract] [Full Text] [Related]
14. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
15. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient.
Moreau C; Debray D; Loriot MA; Taburet AM; Furlan V
Transplantation; 2006 Feb; 81(3):487-8. PubMed ID: 16477241
[No Abstract] [Full Text] [Related]
16. Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres.
Miyamoto Y; Uno T; Yamamoto H; Xiao-Kang L; Sakamoto K; Hashimoto H; Takenaka H; Kawashima Y; Kawarasaki H
Liver Transpl; 2004 Mar; 10(3):392-6. PubMed ID: 15004766
[TBL] [Abstract][Full Text] [Related]
17. Predominant role of local immunosuppressive effect in enhanced efficacy of liposomal FK506 in organ transplantation.
Ko S; Nakajima Y; Kanehiro H; Hisanaga M; Horikawa M; Aomatsu Y; Yagura K; Kin T; Ohyama T; Nishio K; Yamada T; Nakano H
Transplant Proc; 1997; 29(1-2):529-31. PubMed ID: 9123117
[TBL] [Abstract][Full Text] [Related]
18. Choosing the right dose of new immunossuppressive drugs for new populations: importance of pharmacokinetic studies.
Felipe CR; Garcia C; Moreira S; Olsen N; Silva HT; Pestana OM
Transplant Proc; 2001; 33(1-2):1095-6. PubMed ID: 11267207
[No Abstract] [Full Text] [Related]
19. Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure.
Son IJ; Moon YJ; Lee MG; Sohn YT
Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):359-68. PubMed ID: 11958289
[TBL] [Abstract][Full Text] [Related]
20. Trough levels of tacrolimus.
Stolk LM; Van Duijnhoven EM; Christiaans MH; van Hooff JP
Ther Drug Monit; 2002 Aug; 24(4):573; author reply 573-4. PubMed ID: 12142646
[No Abstract] [Full Text] [Related]
[Next] [New Search]
